Zhang, M. et al. Nat Commun 12, 1751 (2021).
Archives: Publications
Publications
Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment
Popat, S. et al. JCO Precis Oncol 5, 39-43 (2021).
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Scagliotti, G. V. et al. Lancet Respir Med 7, 569-580 (2019).
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
van Brummelen, E. M. J. et al. Invest New Drugs 38, 457-467 (2020).
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study
Fennell, D. A. et al. J Clin Oncol 37, 790-798 (2019).
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
Fennell, D. A. et al. Trials 19, 233 (2018).
BTS guideline for the investigation and management of malignant pleural mesothelioma
Woolhouse, I. et al. BMJ Open Respir Res 5, e000266 (2018).
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Maio, M. et al. Lancet Oncol 18, 1261-1273 (2017).
Novel insights into mesothelioma biology and implications for therapy
Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Nat Rev Cancer 17, 475-488 (2017)